PCSK9 inhibitors -- alirocumab (Praluent), evolocumab (Repatha), and inclisiran (Leqvio) -- are injections that keep LDL receptors free to bind to LDL cholesterol and keep it out of the blood ...

Evolocumab (Repatha) was approved for children ages 10 and older with heterozygous and homozygous FH based on a trial showing a 38.3 percentage point greater reduction in LDL cholesterol over 24 ...